Of dual-targeting CAR-T cell therapies, he said, “I think this is the next iteration in CAR. Zamtocabtagene is one of four 20/19 CARs under development and if you look at the data for all of them, they look to be highly efficacious, better than our standard CD19-CAR.”

Listen to more podcasts on sohoinsider.com. 

This program is led by Loretta Nastoupil, MD, the SOHO Insider community oncology section editor.

To register for the series, go to https://soho.click/community-oncology-series

Dr. Iacoboni discussed strategies to improve outcomes in high-grade lymphoma, focusing on improved patient selection, the emergence of dual-targeted CAR T-cell products (CD19/CD20), and how circadian rhythms might impact infusion efficacy. 

Follow more news from SOHO UK.

According to Prof. Goodall, expert leadership is the idea that organizations perform best when leaders are experts in the core work of the institution. As part of this work, she runs an executive master’s program in medical leadership, designed to help physicians develop the skills needed to lead healthcare organizations while maintaining credibility as clinicians.

Her research argues that in healthcare this means placing experienced, high-performing physicians in leadership roles rather than relying primarily on generalist managers. Many doctors, she noted, are interested in leadership because they want to drive meaningful change and improve patient care, but historically they have had limited access to formal leadership training.

The podcast was taped during the inaugural meeting of SOHO UK, where Prof. Goodall gave a talk after dinner on the topic.

Learn about the Executive Master’s in Medical Leadership (EMML) program.

Prof. Cwynarski will chair a “Meet the Expert” roundtable on challenges and controversies in managing central nervous system (CNS) lymphoma. The session will include a seven-year update of the MARIETTA study, which examined treatment strategies for secondary CNS lymphoma, as well as findings from a large real-world evidence study of secondary CNS lymphoma.

She will also lead a session on peripheral T-cell lymphoma focused on the shift toward biologically informed therapy. The presentation will highlight the TERZO study and explore how emerging biologic insights may guide treatment decisions in this heterogeneous group of lymphomas.

The sessions are part of the program for the first SOHO UK meeting, which will bring together global clinicians and researchers to discuss advances in the treatment of blood cancers.

For SOHO 2026, Dr. DiPersio chose the theme “Advancing care through collaborative science,” a timely topic as NIH funding continues to decline.

“SOHO 2026 will explore how public-private partnerships can sustain discovery, preserve basic research, and ensure access to innovation for patients around the world,” Dr. DiPersio said in a recent interview with SOHO Insider.

Register for SOHO 2026 today

Register today for SOHO 2026 at soho.click/2026. SOHO members receive a 40% discount. Join SOHO for free at http://soho.click/join.

In the trial led by Dr. Phillips, the investigators evaluated glofitamab monotherapy in patients with relapsed or refractory B-cell lymphomas, with obinutuzumab pretreatment to mitigate the risk of cytokine release syndrome with glofitamab.

Dr. Phillips also spoke about treating patients with relapsed or refractory non-Hodgkin lymphoma with venetoclax.

Listen to other podcast episodes of SOHO Insider.

“The first thing I do whenever a patient walks into the clinic with ET is think about their risk status,” Dr. Tremblay said. “When we speak about risk status, what we’re really speaking about is risk of thrombosis. There’s several different risk stratification methods, but they all rely on three clinical factors in general, which is age of prior thrombosis, which is probably the most potent risk factor.”

This episode also includes a discussion on the SURPASS-ET trial, which showed ropeginterferon alfa-2b outperformed anagrelide for disease control. Plus, a look into how new CALR-targeted antibodies improve bone marrow in early studies.

Dr. Masarova discusses SURPASS-ET study at EHA 2025

Chase shares his experience traveling to China for the therapy as a heavily-treated patient with limited treatment options. Chase talked about his treatment journey, his experience being treated in a foreign country with an experiment therapy, and what it was like achieving long-term remission.

Dr. Martin also discussed the five-year CARTITUDE-1 follow-up date presented at both ASCO(R) and EHA 2025. Those date showed that one-third of myeloma patients were in remission more than five years after cilta-cel treatment. The results of these trials and other trial data on therapies other than cilta-cel, prompted Sundar Jagannath, MD, during SOHO 2025 to address the potential of using the word cure when speaking with patients.

“To be able to give your patients these novel therapies is amazing,” Dr. Graff said on the podcast. “I think it’s going to be a bispecific-versus-CAR-T world in all the different disease states of lymphoma. But I don’t think I would choose one or the other across the board.”

They also discussed how hematologist-oncologists can support colleagues who have not managed toxicities associated with cell therapies.

“I think we’re just going to have to be patient and really help, because if we don’t help them, all the specialists are going to wind up seeing all the other specialties’ patients,” Dr. Graff said. “And there’s no way we can do that. It’s just being patient and helping each other.”

Listen to more SOHO Insider podcasts.

Read more about Dr. Melody here. 

She noted that the biggest shift in the field is moving away from chemotherapy alone and toward immunotherapy and bispecific-based approaches.

Dr. Vose will be speaking at 12:30 pm Central time on November 20, 2025, during SBBC. At 12:55 pm Central time, attendees can ask questions via the virtual platform.

Major shift toward integrating bispecifcs

Dr. Vose points to a major shift toward integrating bispecifics in combination regimens with chemotherapy to help patients reach CAR-T or transplant, and now increasingly in frontline therapy for diffuse large B-cell lymphoma and follicular lymphoma.

She highlighted both the STARGLO study, a randomized, global, phase 3 study that is evaluating glofitamab plus gemcitabine and oxaliplatin in the relapsed or refractory setting in DLBCL, and the SUNMO phase 3 trial that is evaluating mosunetuzumab plus polatuzumab vedotin to R-GemOx in transplant-ineligible patients with relapsed or refractory LBCL.

There is still time to register at soho.click/SBBC. Registration is free for SOHO members and $50 for non-SOHO members. Join SOHO for free today.

The pair spoke about the novel trispecific antibody JNJ-5322 that targets BCMA and GPRC5D via T-cell redirection and ISB 2001, an investigational trispecific antibody that received FDA fast track designation earlier in 2025.

“The future looks bright for the trispecifics,” Dr. van de Donk said. “We are also looking at combination strategies now in that patients with earlier, lines of therapy, less prior lines of therapy, we are even testing the trispecific now in combination with dara in newly diagnosed patients and the future hopefully again challenging transplant which is still a key component in Europe for the newly diagnosed myeloma patient.

Listen to more SOHO Insider podcasts.

SBBC is a new virtual meeting from SOHO and is chaired by Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center. SBBC takes place at 8 am—5 pm Central time on November 20, 2025. Register today at soho.click/SBBC. To view the entire program, visit the SBBC website. 

SOHO members register for free; $50 for non-SOHO members. To become a SOHO member go to soho.click/join.

Dr. Stein discusses the development of the first menin inhibitor approved the US Food and Drug Administration for relapsed or refractory acute leukemia with a KMTA translocation.

“The response rate is in the range of 60% to 70%,” noted Dr. Stein, including 30% complete remission or partial hematologic recovery.

“I think the big issue with menin inhibitors is that they’re not durable,” Dr. Stein said. “Patients go into remission… for something like six to nine months, but then they eventually relapse.”

About combination therapies, Dr. Stein said the goal was to follow the myeloma treatment paradigm.

“I think that what you all have done in myeloma is what we’re looking to do in leukemia,”he said, adding that the combination therapies will “hopefully lead to more durable remissions and allow more people to have successful … transplants, which seems to be still the best anti-leukemia therapy in 2025.”

Ten years from now, Dr. Stein said he would like to see more intensive therapy upfront.

“10 years from now, what I’m hoping is that transplant is reserved for patients with the highest-risk disease,” he said. “[And] that we’re able to give intensive therapy upfront and then move to a maintenance strategy, where you’re giving targeted agents as your maintenance approach with those targeted agents having many fewer side effects.”

Listen to more episodes. 

 “I put anemia near the top of the list, or at least an equal footing with spleen and symptoms,”  Dr. Gerds said. He also noted that 40% of myelofibrosis patients face anemia at diagnosis, with nearly all affected over time.

The pair discuss causes of anemia in myelofibrosis, such as bone marrow failure and inflammation, which complicate treatment. Past therapies targeted spleen size, but drugs like luspatercept and pelabresib offer hope. “We’re fighting this war on two fronts,” Dr.Gerds said.

Listen to more podcast episodes.